Skip to content
TrialScanner

NCT07573215

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

No phase registeredApproved for marketingRVMDLead

Registry record

Lead sponsor
Revolution Medicines, Inc.
Conditions
PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Metastatic Pancreas Adenocarcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07573215 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.